Nevertheless, because the median patient age at diagnosis of PC has increased over the past 10 years (65 to 70 years), we believe that our results may be valuable when making a decision (primary G-CSF prophylaxis vs. a wait-and-see strategy) in older MPC patients treated with FOLFIRINOX. This evidence concerns the gene CSF3 and pachyonychia congenita.